A broader and stronger generic drug market is promoted in Mexico

Home/Reports | Posted 21/06/2021 post-comment0 Post your comment

During a press conference held on 14 November 2020, ‘A new generic medicines market’ strategy was revealed, with which ’the Health and Economic Secretaries will strengthen the companies producing generic medicines, through the linking mechanisms and technological tools, based on the principles of innovation, transparency, competitiveness and legality’ fostering firmly a wider and solid generic medicines market, for the benefit of Mexican nationals. 

109 MD002387

Hugo López-Gatell, Undersecretary of Prevention and Health Promotion; José Alonso Novelo Baeza, Head of the Federal Commission for the Protection against Sanitary Risks (COFEPRIS); Ernesto Acevedo Fernández, Undersecretary of Industry, Commerce and Competitiveness of the Ministry of Economy, and Juan Lozano Tovar, General Director of the Mexican Institute of Industrial Property (IMPI), participated in the conference.

Hugo López-Gatell pointed out that the goal is to simplify procedures, to establish processes that are not only more efficient but also simpler, traceable and that can be subjected to the formal scrutiny of the supervisory (or audit) bodies and citizens.

The main actions undertaken for the implementation of this initiative include:
1. Modification of the basic table of medicines and supplies, known as the Compendio Nacional de Insumos para la Salud (National Compendium of Health Supplies (CNIS), composed by 14,806 keys
2. Support to the pharmaceutical companies through the elimination of existing bureaucratic barriers, to generate an adequate competitive environment
3. Simplification, efficiency and traceability of the processes and procedures related with generic medicines, which allow the open scrutiny of the supervisory bodies, and even of the public
4. Improvement of the regulatory framework for the protection against health risks
5. Promoting the principles of innovation, transparency, competitiveness, and legality, for the Federal Commission for Protection against Health Risks (Comisión Federal para la Protección contra Riesgos Sanitarios, COFEPRIS) to preserve its technical and management autonomy.

Related articles
Biosimilars in Japan: an overview

Use of generic drugs is promoted in Peru

GPhA comments on generics’ legislation and Trans-Pacific Partnership

Access to generic medicines undermined in free trade agreement

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.


comment icon Comments (0)
Post your comment
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010